An Evaluation of Values of ERCC1 ,K-ras and TP-73 in Tirelizumab Combined with GP Chemotherapy Regimen
Objective The study aims to evaluate values of nucleotide excision repair cross complementary gene 1 (ERCC1),Kirsten Rous sarcoma virus protein (K-ras)and tumor protein P73 (TP73)in the treatment of (non-small cell lung cancer,NSCLC )with tirelizumab combined with paclitaxel+cisplatin (TP ) chemotherapy regimen.Methods 126 NSCLC patients admitted to our hospital from January,2021 to December,2021 were selected as the subjects and randomly divided into a control group and an observation group,with 63 cases in each group.The control group was treated with TP chemotherapy regimen, while the observation group was treated with tirelizumab.We evaluated the clinical efficacy,tumor marker proteins,immune indicators,survival cycle,and adverse reactions between these two groups.Results The objective response rate of the observation group patients was 69.84％(44/63),which was higher than that of the control group patients (52.38％ (33/63).The disease control rate of the observation group was 82.54％ (52/63),and it was higher than that of the control group patients (66.67％ (42/63)(P<0.05).At cycle 1,cycle 3,and cycle 6 of chemotherapy,levels of ERCC1 ,K-ras,and TP-73 in the observation group were lower than those in the control group (P<0.05).After treatment,the immune function of complement C3,complement C4,and CD40 cells in the observation group were lower than those in the control group,while NK cells were higher than those in the control group (P<0.05).TTP,PFS,and overall survival of the observation group patients were higher than those of the control group (P<0.05).The incidence of adverse reactions was 19.05％ (12/63)in the observation group and 12.70％ (8/63)in the control group,with no significant difference between the groups (P>0.05).Conclusion The combination of tirelizumab and TP chemotherapy regimen has a good therapeutic effect in the treatment of lung cancer,which can improve patient immune function,prolong patient survival cycle,and have a good treatment safety. Moreover,changes in ERCC1 , K-ras, and TP-73 levels can reflect the therapeutic effect of tirelizumab combined with TP chemotherapy regimen in lung cancer,and has a high application value in comprehensive efficacy evaluation.
TirelizumabTaxolCisplatinNucleotide excision repair cross complementation group 1Gene kirsten rous sarcoma virus proteinTumor protein P73Non-small cell lung cancer
万方数据
维普
